C91.A2
Mature B-cell leukemia Burkitt-type, in relapse
Clinical Classification Guidelines
Medical Intelligence & Overview
Mature B-cell leukemia Burkitt-type is a form of aggressive blood cancer that originates from B-lymphocytes, a type of white blood cell involved in the immune response. When this condition is described as 'in relapse,' it indicates that the cancer has returned after initial treatment. This type of leukemia shares characteristics with Burkitt lymphoma, a fast-growing cancer that affects lymphatic tissue, but in this case, it involves mature B-cells circulating in the blood and bone marrow. Understanding this disease involves recognizing its rapid progression, typical symptoms, underlying causes, diagnostic methods, and treatment options.
Causes & Symptoms
Clinical Causes: Genetic mutations leading to abnormal B-cell growth Previous exposure to chemotherapy or radiation therapy Inherited genetic predispositions (less common) Viral infections, such as Epstein-Barr virus (EBV), which can influence B-cell proliferation Environmental factors, including exposure to certain chemicals or toxins
Key Symptoms: Rapidly enlarging lymph nodes, often painless Unexplained weight loss Fever and night sweats Fatigue or weakness Pain or swelling in the abdomen due to enlarged spleen or liver Frequent infections due to compromised immune function Easy bruising or bleeding because of low blood platelet counts Anemia-related symptoms like pallor and shortness of breath
Diagnostic & Treatment
Diagnosis Path: Diagnosing mature B-cell leukemia Burkitt-type in relapse involves a combination of clinical evaluation and laboratory tests: - Complete blood count (CBC) to assess blood cell levels - Bone marrow biopsy to examine marrow involvement - Peripheral blood smear to identify abnormal lymphocytes - Imaging tests such as CT scans, PET scans, or MRI to detect enlarged lymph nodes or organ involvement - Immunophenotyping to determine specific cell surface markers - Cytogenetic analysis and molecular testing to identify genetic mutations typical of Burkitt-type leukemia - Lumbar puncture may be performed if central nervous system involvement is suspected
Treatment Protocols: Treatment strategies for relapsed mature B-cell leukemia Burkitt-type involve aggressive approaches, often combining multiple therapies: - Chemotherapy regimens designed to target rapidly dividing cells - Immunotherapy, including monoclonal antibodies such as rituximab, to enhance immune response - Targeted therapy that focuses on specific genetic mutations or pathways - Stem cell or bone marrow transplantation for eligible patients - Supportive care to manage symptoms and prevent complications, such as antibiotics for infections, blood transfusions, and growth factors It is important to note that treatment plans are tailored to individual patients based on their overall health, previous treatments, and disease extent.
Clinical Advice & FAQs
Billing Guidance
Is C91.A2 a billable ICD-10 code?
Yes, C91.A2 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C91.A2?
Clinical documentation must specify the nature of Mature B-cell leukemia Burkitt-type, in relapse and any associated comorbidities for accurate reporting.
Cite this Clinical Reference